September 20th 2024
Peptides are increasingly used in cosmeceuticals for their ability to enhance cellular communication and functionality in antiaging formulations.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Studies demonstrate safety, efficacy of CaHA for facial lipoatrophy
July 1st 2006National report - Results of two parallel, prospective, open-label, North American studies demonstrate that treatment with the injectable filler consisting of microspheres of calcium hydroxylapatite (CaHA) in a carboxymethylcellulose gel carrier (Radiesse, BioForm Medical) provides safe, immediate and relatively durable restoration of facial volume in patients with HIV-associated lipoatrophy.
Immune response modifier post-op
July 1st 2006San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
DT senior editor published in JAMA
July 1st 2006Cleveland - "At Face Value," written by Dermatology Times Senior Editor Karen Donley-Hayes, appeared in the June 21, 2006, issue of the Journal of the American Medical Association (JAMA, Vol.295, No. 23, 2701-2702). A story spurred by the essay was also published on Heathday.com, and Ms. Donley-Hayes was interviewed for the University of Kentucky's Dr. Greg Davis on Medicine program, which aired on WUKY 91.3 FM UK Public Radio.
Treating the mosaic of Asian skin
June 1st 2006Rancho Mirage, Calif. - The Asian population has a spectrumof skin types, from the porcelain white of the Japanese to thebrowner Pacific Islanders, according to Wendy E. Roberts, M.D. Sheis a dermatologist here, and assistant clinical professor ofmedicine at Loma Linda University Medical School, Loma Linda,Calif.
Best Mohs reconstruction is simple, aesthetically pleasing,restores function
June 1st 2006New York - Planning and performing a surgical reconstructionafter Mohs surgery is usually a simple and straightforward task ifthe surgeon follows simple rules and uses simple techniques,according to Michael R. Shohet, M.D., director of facial plasticand reconstructive surgery at the Mount Sinai School of Medicinehere.
Smaller procedures achieve big results
June 1st 2006Norfolk, Va. - Used in combination, minimally invasive lowerface procedures such as botulinum toxin and filler injections andfat grafts can achieve impressive results while making plasticsurgery accessible to more patients, an expert tells DermatologyTimes.